RAS, FLT3, and TP53 Mutations in Therapy-Related Myeloid Malignancies with Abnormalities of Chromosomes 5 and 7

Genes Chromosomes and Cancer

Volumn 39, Issue 3, 2004, Pages 217-223

  Side, Lucy E ^a   Curtiss, Nicole P ^a   Teel, Kathryn ^a   Kratz, Christian ^a   Wang, Pauline W ^b   Larson, Richard A ^b   Le Beau, Michelle M ^b   Shannon, Kevin M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; FETAL LIVER KINASE 3; FETAL LIVER KINASE-3; FLT3 LIGAND; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER; CELL PROLIFERATION; CHILD; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE DUPLICATION; GENE MUTATION; GENETICS; HUMAN; LEUKEMIA CELL; MALE; MONOSOMY 7; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SECOND CANCER;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1142310671     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10320     Document Type: Article

References (53)

1. Allay E, Veigl M, Gerson SL. 1999. Mice over-expressing human 06 alkylguanine-DNA alkyltransferase selectively reduce 06 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene 18:3783-3787.
2. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O, Rachmilewitz EA. 1996. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88:4296-4303.
3. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551-2556.
4. Christiansen DH, Pedersen-Bjergaard J. 2001. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. Leukemia 15:1848-1851.
5. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2001. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405-1413.
6. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH. 1996. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85:853-861.
7. Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
8. Donovan S, Shannon KM, Bollag G. 2002. GTPase activating poteins: critical regulators of intracellular signaling. BBA Rev Cancer 1602:23-45.
9. Downing JR, Shannon KM. 2002. Acute leukemia: a pediatric perspective. Cancer Cell 2:437-445.
10. Dumenco LL, Allay E, Norton K, Gerson SL. 1993. The prevention of thymic lymphomas in transgenic mice by human O6-alkylgua-nine-DNA alkyltransferase. Science 259:219-222.
11. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. 1991. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652-1657.
12. Gilliland DG, Tallman MS. 2002. Focus on acute leukemias. Cancer Cell 1:417-420.
13. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T. 2000. Tandem-duplicated Flt3 constitutively activates STAT5, MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631.
14. Higuchi M, O'Brien D, Kumaravelu P, Lenney N, Yeoh E, Downing JR. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine mode[of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74.
15. Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, Tanaka S, Yagita M, Abe T, Kashima K, Taniwaki M. 1999. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 13:1235-1242.
16. ras. Blood 84:3435-3439.
17. Kamada N, Tanaka K, Oguma N, Mabuchi K. 1991. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J Radiat Res Suppl 2:257-265.
18. Kelly L, Clark J, Gilliland DG. 2002a. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Curr Opin Oncol 14:10-18.
19. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. 2002b. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99:310-318.
20. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080.
21. Kratz CP, Emerling BM, Donovan S, Laig-Webster M, Taylor BR, Thompson P, Jensen S, Banerjee A, Bonifas J, Makalowski W, Green ED, Le Beau MM, Shannon KM. 2001. Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. Genomics 77:171-180.
22. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R, 3rd, Zhao N, Pamintuan L, Till BG, Larson RA, Qian Z, Le Beau MM. 2001. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 71:235-245.
23. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P. 1995. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9:370-381.
24. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. 1996. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat Genet 12:137-143.
25. Le Beau M, Albain KS, Larson RA, Vardiman J, Davis E, Blough R, Golomb H, Rowley J. 1986. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalties of chromosomes 5 and 7. J Clin Oncol 3:325-345.
26. Le Beau MM, Espinosa RE III, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA. 1993. Cytogenetic, molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 90:5484-5488.
27. Le Beau MM, Espinosa R 3rd, Davis EM, Eisenbart JD, Larson RA, Green ED. 1996. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88:1930-1935.
28. Liu L, Allay E, Dumenco LL, Gerson SL. 1994. Rapid repair of O6-methy[guanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res 54:4648-4652.
29. Mahgoub N, Taylor B, Le Beau M, Gratiot M, Carlson K, Jacks T, Shannon KM. 1999. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 93:3617-3623.
30. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Lange BJ, Shannon KM. 1997. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79:1438-1446.
31. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner T, Kienast J, Kanakura Y, Berdel WE, Serve H. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-3914.
32. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, Naoe T. 1999. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 104:659-664.
33. Neubauer A, Shannon KM, Liu E. 1991. Mutations of the ras proto-oncogenes in childhood monosomy 7. Blood 77:594-598.
34. Osaka M, Matsuo S, Koh T, Liang P, Kinoshita H, Maeda S, Sugiyama T. 1995. N-ras mutations in 7,12-dimethylbenz[a]anthracene (DMBA)-induced erythroleukemia in Long-Evans rats. Cancer Lett 91:25-31.
35. Pedersen-Bjergaard J. 1992. Radiotherapy and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 16:61-65.
36. Pedersen-Bjergaard J, Janssen JWG, Lyons J. 1988. Point mutations of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res 48:1812-1817.
37. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. 2002. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99:1909-1912.
38. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. 2002. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 99:14925-14930.
39. Rowley JD, Golomb HM, Vardiman J. 1977. Acute leukemia after treatment of lymphoma [letter]. N Engl J Med 297:1013.
40. Sawyers CL, Denny CT. 1994. Chronic myelomonocytic leukemia: tel-a-kinase what Ets all about. Cell 77:171-173.
41. Schmitt CA, Rosenthal CT, Lowe SW. 2000. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029-1035.
42. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. 2002a. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335-346.
43. Schmitt CA, Yang M, Fridman JS, Baranov E, Hoffman RM, Lowe SW. 2002b. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298.
44. Shannon KM, Watterson J, Johnson P, O'Connell P, Lange B, Shah N, Kan YW, Priest JR. 1992. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 79:1311-1318.
45. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597-601.
46. Side LE, Teel K, Wang P, Mahgoub N, Larson R, Le Beau MM, Shannon KM. 1996. Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7 (abstract). Blood 88(Suppl 1):566a.
47. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. 2003. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102:43-52.
48. Stephenson J, Lizhen H and Mufti GJ. 1995. Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. Leuk Res 19:741-748.
49. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. 2001. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-3595.
50. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. 1990. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5:1037-1043.
51. Taylor JA, Sandler DP, Bloomsfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. 1992. ras Oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Ca Inst 84:1626-1632.
52. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, IIlmer T. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335.
53. Thirman MJ, Larson RA. 1996. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 10:293-320.